1. Kaldara-Papatheodorou EE, Terrovitis JV, Nanas JN. Anemia in heart failure: should we supplement iron in patients with chronic heart failure? Pol Arch Med Wewn 2010; 120 (9): 354–60.
2. Silverberg DS, Wexler D, Blum M, Keren G et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35 (7): 1737–44.
3. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41 (11): 1933–9.
4. Anand I, McMurray JJ, Whitmore J, Warren M et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110 (2): 149–54.
5. Anker SD, Comin Colet J, Filippatos G, Willenheimer R et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361 (25): 2436–48.
6. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003; 107: 223–5.
7. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008; 52 (7): 501–11.
8. He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15 (3): 123–30.
9. Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52 (10): 818–27.
10. Muzzarelli S, Pfisterer M. TIME Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006; 152 (5): 991–6.
11. Vaglio J, Safley DM, Rahman M et al. Relation of anemia at discharge to survival after acute coronary syndromes. Am J Cardiol 2005; 96 (4): 496–9.
12. Dunlay SM, Weston SA, Redfield MS et al. Anemia and heart failure: A community study. Am J Med 2008; 121 (8): 726–32.
13. Go AS, Yang J, Ackerson LM et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113 (23): 2713–23.
14. Sharma S, Gage BF, Deych E et al. Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J 2009; 157 (6): 1057–63.
15. Anand IS, Kuskowski MA, Rector TS, Florea VG et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112 (8): 1121–7.
16. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26 (4): 296–306.
17. Левина А.А., Казюкова Т.В., Цветаева Н.В., Сергеева А.И. и др. Гепсидин как регулятор гомеостаза железа. Педиатрия. 2008; 87 (1): 67–74.
18. Opasich C, Cazzola M, Scelsi L, De Feo S et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26 (21): 2232–7.
19. NanasJN, MatsoukaC, KarageorgopoulosD, LeontiA et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48 (12): 2485–9.
20. JankowskaEA, RozentrytP, WitkowskaA, NowakJ et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31 (15): 1872–80.
21. VanderPuttenK, BraamB, JieKE, GaillardCA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008; 4 (1): 47–57.
22. Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294–9.
23. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141–6.
24. Palazzuoli A, Silverberg D, Iovine F, Capobianco S et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152 (6): 1096 e9–15.
25. Ngo K, Kotecha D, Walters JA, Manzano L et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; (1): CD007613.
26. Van der Meer P, Lipsic E, van Gilst WH, van Veldhuisen DJ. Anemia and erythropoietin in heart failure. Heart Fail Monit 2008; 6 (1): 28–33.
27. Ghali JK, Anand IS, Abraham WT, Fonarow GC et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117 (4): 526–35.
28. McMurray JJ, Anand IS, Diaz R, Maggioni AP et al. RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11 (8): 795–801.
29. Okonko DO, Grzeslo A, Witkowski T, Mandal AK et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51 (2): 103–12.
30. Silverberg DS, Wexler D, Sheps D, Blum M et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37 (7): 1775–80.
31. Silverberg DS, Wexler D, Blum M, Sheps D. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 21 (Suppl. 3): S236–40.
32. Bolger AP, Bartlett FR, Penston HS, O'Leary J et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48 (6): 1225–7.
33. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50 (17): 1657–65.
34. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D et al. Card Fail. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. 2007; 13 (1): 14–7.
35. Usmanov RI, Zueva EB, Silverberg DS et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21 (2): 236–42.
36. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr1970; 100 (7): 301–3.
37. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Кардиоваск. тер. и профилакт. 2008; 7 (6) Прил. 3.
38. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm
39. Locatelli F, Aljama P, Canaud B, Covic A et al. Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25 (9): 2846–50.

О.А.Эттингер, О.В.Ускова, Г.Е.Гендлин, Г.И.Сторожаков 

ГОУ ВПО Российский государственный медицинский университет им. Н.И.Пирогова Минздравсоцразвития РФ, Москва